Insud Pharma
Laura Ramiro Gonzalez has extensive work experience in various roles related to talent management, recruitment, and human resources. Laura began their career at Champion in 2000, where they worked in recruitment until 2001. Laura then joined Catenon as a project manager from 2001 to 2008. In 2008, Laura moved to Insud Pharma and held multiple positions, including Global Recruitment Manager from 2008 to 2019, People BP mAbxience & Corporate from 2019 to present, and Talent Management Associate Director & HRBP Corporate from 2023 to present.
Laura Ramiro Gonzalez received their Licenciada degree in Psychology from the Universidad Autónoma de Madrid from 1995 to 2000. Prior to that, they attended the Liceo Scientifico from 1980 to 1995.
This person is not in the org chart
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.